pancreatic-cancer

Documents about pancreatic-cancer

• Study of LT-010391 in Participants With KRAS G12D-Mutant Solid Tumors#833361ClinicalTrials.gov
• KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors#158233ClinicalTrials.gov
• TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers#902640ClinicalTrials.gov
• Multi-center, Open-label, Phase 1b Clinical Trial to Evaluate the Safety, Tolerability, and Exploratory Efficacy of TEW-7197 in Combination With FOLFOX in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed First-Line Gemcitabine and Nab-Paclitaxel#394672ClinicalTrials.gov
• A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy#908639ClinicalTrials.gov
• A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors#890578ClinicalTrials.gov
• Optional Sub-study to Intraoperative Imaging With ICG Registry#843472ClinicalTrials.gov
• The Joint Global Epidemiology of Pancreatic Cancer and Pancreatitis: Co-Occurrence Patterns, Shared Risk Factors, and Projections to 2040.#722NCBI PubMed Central
• Interpretable miRNA-based prediction model for early detection of pancreatic cancer: Development and cross-platform validation#159608Unpaywall
• Use of large language models as clinical decision support tools for management pancreatic adenocarcinoma using National Comprehensive Cancer Network guidelines.#209465NCBI PubMed Central
• KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors#414486ClinicalTrials.gov
• Predictive value of 18F-FDG PET/CT delta radiomics model for prognosis after neoadjuvant therapy for locally advanced pancreatic cancer.#455298NCBI PubMed Central
• The kinase ERK plays a conserved dominant role in the heterogeneity of epithelial-mesenchymal transition in pancreatic cancer cells.#625967NCBI PubMed Central
• Combining Epigenetic And Immune Therapy to Beat Cancer.#668813ClinicalTrials.gov
• Ketamine-midazolam as a Sedative Agent in Endoscopic Retrograde Cholangiopancreatography.#853297ClinicalTrials.gov
• Efficacy of Fistulotomy for Biliary Cannulation#880434ClinicalTrials.gov
• Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients#898174ClinicalTrials.gov
• FOLFIRINOX in Patients With Inoperable Pancreatic Cancer#898762ClinicalTrials.gov
• A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies#812777ClinicalTrials.gov
• A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers#858858ClinicalTrials.gov
• Theranostic Approach by Early Multigene Sequencing in Advanced Poor Prognosis Cancers#904478ClinicalTrials.gov
• A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.#373613ClinicalTrials.gov
• Dual Metabolic Blockade in Pancreatic Cancer: Potent Anticancer Activity of Mitochondria-Targeted Glycolysis and OXPHOS Inhibitors#212901Figshare
• Dual Metabolic Blockade in Pancreatic Cancer: Potent Anticancer Activity of Mitochondria-Targeted Glycolysis and OXPHOS Inhibitors#212902Figshare
• Development and prognostic evaluation of an integrative programmed cell death index in pancreatic cancer based on multiple cell death modalities.#154325NCBI PubMed Central
• Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors#195413ClinicalTrials.gov
• Effect of polyunsaturated fatty acids supplementation on nutritional status in patients with pancreatic cancer: a systematic review and meta-analysis.#224880NCBI PubMed Central
• Overweight status drives early tumor microenvironment reprogramming in pancreatic ductal adenocarcinoma: a cell-type-resolved Bayesian hierarchical modeling and interactome analysis#279385bioRxiv / medRxiv
• Engineered Lipid Nanoparticles with Promoted Endosomal Escape and R283S-Mediated Stimulator of Interferon Genes (STING) Activation for Pancreatic Cancer Immunotherapy.#317875NCBI PubMed Central
• A single-cell and machine learning framework identifies CAFs-associated signatures linking stromal heterogeneity to immune regulation in pancreatic cancer.#360644NCBI PubMed Central
• Precision Therapeutics in Pancreatic Cancer: Emerging Targeted, Immune, and Antibody-Drug Conjugate Strategies Exemplified by Adagrasib, Dostarlimab, and Trastuzumab Deruxtecan.#409297NCBI PubMed Central
• Performance of risk prediction models for pancreatic cancer in patients with new-onset diabetes: a systematic review and meta-analysis.#636307NCBI PubMed Central
• GAN-enhanced Machine Learning and Metabolic Modeling Identify Reprogramming in Pancreatic Cancer#658337DigitalCommons@University of Nebraska
• HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors#902510ClinicalTrials.gov
• Self-Assembled Nucleolipid G-Quadruplexes Act as Multitarget Decoys for Oncogene Suppression in Pancreatic Cancer#156703Unpaywall
• Efficacy and Safety Assessment of 5-Fluorouracil, Irinotecan and Oxaliplatin-Loaded Implants in Mouse and Pig Models for Pancreatic Cancer Therapy.#165740NCBI PubMed Central
• Next-generation AI for visually occult pancreatic cancer detection in a low-prevalence setting with longitudinal stability and multi-institutional generalisability.#269471NCBI PubMed Central
• Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer & Liver Metastases#287548ClinicalTrials.gov
• AG Combined With Cadonilimab Sequential Short-course Radiotherapy in the Treatment of Locally aPDAC#810286ClinicalTrials.gov
• HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer#910810ClinicalTrials.gov
• A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies#830569ClinicalTrials.gov
• Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI#846956ClinicalTrials.gov
• A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors#234504ClinicalTrials.gov
• Biomarker discovery and patient stratification in pancreatic cancer using incomplete multi-omics data#679671PLOS
• Clinical Outcomes for Offering Genetic Testing in a Tiered Approach#801837ClinicalTrials.gov
• Spanish Registry of Direct Cholangiopancreatoscopy by Single Operator#883139ClinicalTrials.gov
• Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation#886723ClinicalTrials.gov
• Sub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors -Clinical Application Value of PET Imaging Targeting LRRC15 in Malignant Tumors#855686ClinicalTrials.gov
• Targeting CEA in Pancreas Cancer Xenografts with a Mutated scFv-Fc Antibody Fragment#612106eScholarship
• Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors#876209ClinicalTrials.gov